oral medication
| 2 min read
New data suggests icotrokinra could challenge injectables with once-daily targeted peptide.
| 1 min read
Cyprumed GmbH and MSD have entered a non-exclusive agreement to develop oral peptide formulations using Cyprumed’s delivery technology.
| 4 min read
Elizabeth Laws leads Sanofi’s inflammation and immunology development pipeline to test the first oral TNFR1 inhibitor for rheumatoid arthritis and psoriasis.
Page 1 of 1 - 3 Total Items
